Patient demographic and clinical characteristics
| Characteristic | Group; no. (%) of patients* | p value† | ||
|---|---|---|---|---|
| PCC n = 26 | Vitamin K n = 65 | Control n = 50 | ||
| Age, median (IQR), yr | 85 (78–90) | 86 (81–89) | 87 (82–89) | 0.7 |
| Male sex | 2 (8)‡ | 24 (37) | 14 (28) | 0.02 |
| Weight, median (IQR), kg | 61 (55–74) | 65 (55–75) | 60 (50–70) | 0.06 |
| Body mass index, median (IQR) | 24 (21–27) | 23 (21–26) | 22 (20–24) | 0.07 |
| ASA score | 0.04 | |||
| 2 | 4 (15) | 18 (28) | 24 (48) | — |
| 3 | 20 (77) | 42 (65) | 24 (48) | — |
| 4 | 2 (8) | 5 (8) | 2 (4) | — |
| Charlson Comorbidity Index score, median (IQR) | 5 (4–7) | 6 (5–7) | 5 (4–7)‡ | 0.02 |
| Surgical procedure | 0.99 | |||
| Hip replacement | 11 (42) | 28 (43) | 22 (44) | — |
| Other | 15 (58) | 37 (57) | 28 (56) | — |
| Type of fracture | 0.99 | |||
| Neck | 13 (50) | 33 (51) | 25 (50) | — |
| Trochanter | 13 (50) | 32 (49) | 25 (50) | — |
| Indication for VKA | 0.3 | |||
| Atrial fibrillation | 21 (81) | 44 (68) | — | — |
| Deep vein thrombosis/pulmonary embolism | 2 (8) | 13 (20) | — | — |
| Other | 3 (12) | 8 (12) | — | — |
ASA = American Society of Anesthesiologists; IQR = interquartile range; PCC =prothrombin complex concentrate; VKA = vitamin K antagonist.
↵* Except where noted otherwise.
↵† For between-group differences determined with the χ2 test with post hoc test, or Kruskal–Wallis test with post hoc analysis with the Dunn test and Bonferroni correction.
↵‡ p < 0.05 for difference with vitamin K group.